Investigator’s Meeting for the TRS Phase 3 study

The RemediumOne team, together with our Principal Investigators Prof. Sambasivamoorthy Sivayokan and Dr. Gayani Punchihewa for the TRS (Treatment-Resistant Schizophrenia) Study, attended the Investigator’s Meeting (IM) hosted at Taj Samudra, Colombo. The IM brought together site teams to align on the study protocol, safety procedures, and operational best practices for the trial.

This Phase III, 52-week, multi-center, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy, safety, and tolerability of fixed doses of Evenamide (15 mg BID and 30 mg BID) as an add-on therapy in patients with documented treatment-resistant schizophrenia.

Through collaborative discussions and training sessions, the teams reinforced their commitment to maintaining the highest standards of patient safety, data integrity, and ethical research practices.

We extend our gratitude to all participating investigators, study teams, and partners, including CliniRx, for their dedication to advancing mental health research in Sri Lanka. Together, we are paving the way for innovative treatments and improved outcomes for patients worldwide.